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Genetic and cellular studies highlight that
A Disintegrin and Metalloproteinase 19 is a
protective biomarker in human prostate
cancer
Gerard Hoyne1, Caroline Rudnicka2, Qing-Xiang Sang3, Mark Roycik3, Sarah Howarth1,4, Peter Leedman4,5,
Markus Schlaich5, Patrick Candy4 and Vance Matthews4,5,6*
Abstract
Background: Prostate cancer is the second most frequently diagnosed cancer in men worldwide. Current treatments
include surgery, androgen ablation and radiation. Introduction of more targeted therapies in prostate cancer, based on
a detailed knowledge of the signalling pathways, aims to reduce side effects, leading to better clinical outcomes for
the patient. ADAM19 (A Disintegrin And Metalloproteinase 19) is a transmembrane and soluble protein which can
regulate cell phenotype through cell adhesion and proteolysis. ADAM19 has been positively associated with numerous
diseases, but has not been shown to be a tumor suppressor in the pathogenesis of any human cancers. Our group
sought to investigate the role of ADAM19 in human prostate cancer.
Methods: ADAM19 mRNA and protein levels were assessed in well characterised human prostate cancer cohorts.
ADAM19 expression was assessed in normal prostate epithelial cells (RWPE-1) and prostate cancer cells (LNCaP, PC3)
using western blotting and immunocytochemistry. Proliferation assays were conducted in LNCaP cells in which
ADAM19 was over-expressed. In vitro scratch assays were performed in PC3 cells over-expressing ADAM19.
Results: Immunohistochemical studies highlighted that ADAM19 protein levels were elevated in normal prostate tissue
compared to prostate cancer biopsies. Results from the clinical cohorts demonstrated that high levels of ADAM19 in
microarrays are positively associated with lower stage (p = 0.02591) and reduced relapse (p = 0.00277) of human
prostate cancer. In vitro, ADAM19 expression was higher in RWPE-1 cells compared to LNCaP cells. In addition, human
ADAM19 over-expression reduced LNCaP cell proliferation and PC3 cell migration.
Conclusions: Taken together, our immunohistochemical and microarray results and cellular studies have shown for the
first time that ADAM19 is a protective factor for human prostate cancer. Further, this study suggests that upregulation
of ADAM19 expression could be of therapeutic potential in human prostate cancer.
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Background
Recent estimates suggest that 1.1 million cases of pros-
tate cancer were diagnosed worldwide [1]. Prostate can-
cer is the second most common cancer in men, and the
fifth most common cause of cancer-related deaths in
men [1]. The age-adjusted incidence of prostate cancer
has risen in line with an increase in the number of men
being tested and improvements in widespread diagnostic
testing [1].
Early-stage prostate cancer tumours require androgens
as growth factors for proliferation and survival [2]. An-
drogen deprivation may be successfully implemented to
treat androgen-dependent prostate cancer tissue, but is
ineffective at treating androgen-independent prostate
cancer tissue [3]. Androgen ablation therapy also im-
pacts the growth and survival of normal prostate epithe-
lium [2] and has an undesirable effect on body
composition and other physiological and metabolic pa-
rameters, thus increasing the risks for other diseases,
such as osteoporosis [4]. Increased specificity of treat-
ment reduces the risk of these side effects and is more
likely to result in long term decreases in proliferation
and metastasis of cancer, leading to improved clinical
outcomes [5]. It is therefore important to further de-
velop treatment options which specifically target pros-
tate cancer cells [5].
Numerous mechanisms underlying the pathogenesis of
prostate cancer have been identified. For example, en-
hanced levels of the mitogen insulin-like growth factor 1
(IGF-1) and low levels of IGFBP-3 are associated with a
higher risk of prostate cancer [6]. Previous studies have
also indicated that inhibition of the IGF-1 receptor re-
duced invasive activity of PC-3 human prostate cancer
cells [7]. There is still a real need to understand novel
mechanisms that underlie prostate cancer pathogenesis.
Metalloproteinases, or ADAM proteins (A Disintegrin
And Metalloproteinase), are proteolytic enzymes that are
linked with the malignant progression of human prostate
cancer [8]. ADAMs are a family of transmembrane and
secreted proteins which regulate cell phenotype through
affecting cell adhesion, migration, proteolysis and
signalling [8]. Twenty-one human ADAMs have been
described and many have been positively associated with
the pathogenesis of human prostate cancer. ADAM9
expression is significantly higher in prostate cancer tis-
sue than normal prostate tissue [9] and inhibition of
ADAM9 expression in prostate cancer enhanced pros-
tate cancer sensitivity to radiation and chemotherapy
[10]. Knockdown of ADAM10 decreased proliferation of
prostate cancer cells, suggesting that ADAM10 may con-
tribute to the progression of prostate cancer by increas-
ing proliferation [11]. ADAM15 has been shown to
contribute to the metastatic progression of human pros-
tate cancer through the binding of its disintegrin domain
to various integrins [12]. Finally, Xiao et al. [13] showed
that ADAM 17 increased the invasive capacity of pros-
tate cancer cells by targeting matrix metalloproteinases
(MMPs) two and nine.
ADAM19, also known as meltrin β, was identified and
characterised by our team [14, 15] and others [16].
ADAM19 has been linked to numerous diseases [14]
and serves important biological functions in embryo-
genesis [17], cardiovascular system development [18]
and in skeletal muscle adaptation [19]. ADAM19 con-
tains several domains, including a prodomain, metallo-
proteinase domain, disintegrin domain, cysteine-rich
domain, epidermal growth factor-like domain, trans-
membrane domain and cytoplasmic tail domain [8].
The metalloproteinase domain of ADAM19 is known
to be involved in extracellular matrix breakdown and
reconstruction [15]. One of the most important func-
tions carried out by the metalloproteinase domain of
ADAM19 is the catalytically-mediated ectodomain
shedding of substrates [15]. The disintegrin domain of
ADAM19 functions as an adhesion domain by binding
to integrins α4β1 and α5β1 and inhibiting their func-
tion [20]. Importantly, both of these integrins have been
implicated in the development of cancer metastases, in-
cluding that of prostate cancer [21].
Based on the emerging evidence of ADAM involve-
ment in human cancer, we were interested to investigate
if ADAM19 might play a role in prostate cancer using a
combination of clinical cohorts and in vitro analyses.
We found that ADAM19 is a tumor suppressor in hu-
man prostate cancer patients and that it inhibits prostate
cancer cell proliferation and migration in cell culture.
Methods
ADAM19 immunohistochemistry
ADAM19 immunohistochemistry was conducted on hu-
man prostate cancer samples contained on the Prostate
Cancer Tissue Array (Abcam, #ab178263). We person-
ally did not have to gain ethics approval as samples
were part of a commercially available tissue array. All
tissue was examined/diagnosed by a licensed patholo-
gist and was ethically obtained. Immunohistochemistry
was conducted using standard procedures with primary
antibody (rabbit anti-hADAM19 disintegrin domain
IgG (pAb362)) at a 1:200 dilution [22, 23].
Secondary analysis of gene expression omnibus (GEO)
gene expression microarray data
A human prostate cancer microarray of 71 patients
(GEO accession number: GSE40272) contained informa-
tion on ADAM19 gene expression in human prostate tu-
mours, and was processed using the R ‘affy’ and ‘limma’
packages. In addition, we investigated the clinical signifi-
cance of human ADAM19 expression in human prostate
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cancer tumour tissue in this cohort of patients, as follow
up clinical data was available.
We also analysed intratumoural RNA-seq expression
data from a cohort of 156 patients with prostate can-
cer available at The Cancer Genome Atlas (TCGA) (http://
tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp); accessed June
2013). This cohort consisted of 65 patients with pathologic-
ally determined stage II prostate cancer, 85 patients
with stage III, 5 patients with stage IV prostate cancer
and one patient of unknown staging. The mean age of
patients in this cohort was 60.3 years.
We personally did not have to gain ethics approval as
analysis was performed on publicly available microarray
data. The Cancer Genome Atlas (TCGA) is advised by
an External Scientific Committee whose membership in-
cludes patient advocates, senior scientists and clinicians
with relevant expertise in ethics. All prostate samples
used in the GSE40272 related study were collected with
patient’s informed consent under an Institutional Review
Board approved protocol.
Cell culture experiments
Normal human epithelial prostate cells (RWPE-1), which
express the androgen receptor, were compared with an-
drogen sensitive, human prostate cancer cells (LNCaP).
Androgen independent human prostate cancer cells
(PC3) were used for in vitro scratch assays due to their
ability to produce a monolayer in culture. Human em-
bryonic kidney cells (HEK293) were used for tumor ne-
crosis factor-α (TNF-α) shedding experiments.
All cells were purchased from the American Type
Culture Collection (Manassas, VA, USA). HEK293 cells
were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) [low glucose; Gibco] containing 10 % fetal calf
serum (FCS) and 1 % penicillin/streptomycin (Invitrogen,
USA). RWPE-1 cells were cultured in Keratinocyte Serum
Free Medium (K-SFM; GIBCO) containing 0.05 mg/ml
bovine pituitary extract (BPE) and 5 ng/ml human re-
combinant epidermal growth factor (EGF) provided
with the K-SFM kit. LNCaP and PC3 cells were cul-
tured in Roswell Park Memorial Institute-1640 media
(RPMI) (Sigma-Aldrich, Germany) with 10 % FCS and
1 % Penicillin/Streptomycin. To maintain viable healthy
and undifferentiated cells, RWPE-1, LNCaP and PC3
cells were maintained until they reached 70 % con-
fluency and were then transferred into a 75 cm2 flask.
Cells were split into 6 well Cell Bind (Costar), 12 well
Cell Bind (Costar) or 96 well cell culture plates for fur-
ther studies.
Determination of protein expression
LNCaP and RWPE-1 cells were harvested and washed
with cold 1X PBS. Cells were lysed using cytosolic extrac-
tion buffer (10 mM hydroxyethyl piperazineethanesulfonic
acid; 3 mM MgCl2; 14 mM KCl; 5 % glycerol; 0.2 % IGE-
PAL) containing phosphatase and protease inhibitors
(Roche). Cells were then scraped and lysates were trans-
ferred to a 1.5 mL eppendorf tube and stored at -80 °C.
After 24 h, lysates were centrifuged at 13 000 rpm at 4 °C
for 10 min. Bradford assay (Bio-Rad, Hercules, CA, USA)
was used to determine protein concentrations. Protein ly-
sates (40 μg) were solubilized in Laemmeli sample buffer
and boiled for 10 min, resolved by sodium dodecyl sulfate
(SDS)–polyacrylamide gel electrophoresis on 10 % poly-
acrylamide gels, transferred by semi-dry transfer to polyvi-
nylidene difluoride membrane and blocked with 5 % milk
powder. Membranes were then incubated overnight at
4 °C in primary antibodies [rabbit anti-hADAM19 me-
talloproteinase domain IgG (pAb361) [22] or mouse
anti-β-actin (Abcam, Cambridge, UK; ab6276)] using
recommended dilutions. Membranes were washed three
times in washing buffer and incubated for 60 min at
room temperature with either anti-rabbit or anti-mouse
horse-radish peroxidase (HRP; Sigma, USA) respect-
ively. Membranes were then washed and briefly incu-
bated in Amersham ECL Prime Western Blotting
Detection Reagent (GE). The protein bands were de-
tected using the Alpha Innotech MultiImage II Fluor
Chem FC2.
Cell transfections
Transfections were conducted in 6 or 12 well Cell Bind
(Costar) culture plates. Transfection was carried out
once adherent HEK293 or PC-3 cells reached approxi-
mately 70 % confluency using Lipofectamine™ 2000
(Invitrogen, Calsbad, California, USA). Alternatively,
LNCaP cells were transfected in suspension. Cells were
transfected with either pcDNA3.1 GFP vector (Invitro-
gen), empty pCR3.1 vector [23] or vectors containing
the cDNA for human ADAM19 (pCR3.1 hADAM19)
[23] or human TNF-α (pcDNA3.1 (-) pro-TNF-α) [24].
Cells were incubated at 37 °C, in 95 % O2/5 % CO2.
Cells were visualised for GFP using the Nikon Eclipse
Ti microscope to evaluate transfection efficiency after
24 and 48 h. Cell-free culture supernatants were col-
lected after 48 h. Transfected cells were then used for
immunocytochemistry to evaluate ADAM19 expres-
sion. In addition, ADAM19 transfected cells were used
in MTS proliferation assays or migration studies. Empty
vector-transfected cells were used as a comparative
control.
Immunocytochemistry
Immunocytochemistry was used to confirm basal level
and over-expression of human ADAM19 in LNCaP,
RWPE-1, PC-3 and HEK293 cell lines. Cells were fixed
in methanol/acetone (1:1) and endogenous peroxidases
blocked using 0.3 % hydrogen peroxide in Triton X/PBS
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(Tx/PBS) for 5 min. Cells were blocked for 1 h in 10 %
FCS/Tx/PBS, incubated with primary antibody (rabbit
anti-hADAM19 disintegrin domain IgG (pAb362) [23])
at 4 °C overnight, washed 3X in Tx/PBS for 5 min before
a secondary antibody [anti-rabbit horse-radish peroxid-
ase (HRP) (Sigma, USA) diluted 1:100 in blocking buffer
(10 % FCS/Tx/PBS)] was added for 45 min. Cells were
washed 2X in Tx/PBS for 5 min before diaminobenzi-
dine (DAB, DAKO) was added for approximately
10 min and cells were then visualised. Negative controls
had the primary antibody omitted which resulted in no
staining. Cells were visualised using the Nikon Eclipse
Ti microscope.
MTS assay
Transfected and untransfected LNCaP cells were resus-
pended at 0.25x105 cells/mL in RPMI-1640 medium
containing 10 % FCS and 1 % streptomycin/ penicillin
and added in 100 μl volumes to the centre of the wells
of a 96-well culture plate. This technique allowed even
dispersion of cells in the well. We plated 12 samples per
cell type per treatment per time point. After 1, 3, 5 and
7 days, the medium was carefully aspirated and 100 μl
RPMI-1640 medium containing 10 % FCS and 1 %
streptomycin penicillin containing 20 μl of MTS assay
reagent was added to each well for 3 h. After incuba-
tion at 37 °C, in 95 % O2/5 % CO2, proliferation was
determined by MTS assay. Plates were read at 490 nm
(0.1 s per well) on a plate reader. The Nikon Eclipse Ti
microscope was used at each required time point to
image cells.
TNF-α ELISA
Human TNF-α in the cell-free culture supernatant col-
lected from transfected HEK293 or PC3 cells was
measured using a commercially available enzyme-linked
immunosorbent assay kit (TNF-α; R&D Systems, DY210).
In vitro scratch assay
Migration of transfected PC3 cells was assessed using an
in vitro scratch assay [25]. Cell death was determined
with trypan blue cell counting.
Statistics
Statistical analysis of microarrays was performed using
the R programming environment. The Kaplan-Meier
survival curve was based on unadjusted Cox regression
of GSE40272 data using the R “survival” package. The
median was used to divide tumours into high or low
intratumoral ADAM19 expressing groups for compari-
son with longitudinal survival.
The TCGA boxplot was produced using the R “graph-
ics” package and showed the correlation between
tumour stage and human ADAM19 expression. This
data was additionally assessed using Pearson’s product
moment correlation. Statistician Dr. Patrick Candy
performed the microarray statistical analysis (Harry
Perkins Institute of Medical Research, University of
Western Australia, Australia).
In the cell culture experiments, all data was analysed
from three independent experiments and data was statis-
tically analysed using paired t-tests where appropriate.
Statistical significance was determined if the probability
of the null hypothesis was less than 0.05 (p ≤ 0.05).
GraphPad Prism6 was used to plot the data (GraphPad
Software, Inc., LaJolla, CA).
Results
Human prostate carcinoma tissue displays lower ADAM19
expression
Human prostate tumour biopsies and normal prostate tis-
sue samples on a Prostate Cancer Tissue Array were im-
munostained for ADAM19. In normal human prostate
tissue, ADAM19 is highly expressed on the luminal sur-
face of glandular epithelial cells as indicated by brown dia-
minobenzidene staining (Fig. 1a). Excitingly, we report for
the first time that human prostate carcinoma samples
have low ADAM19 expression (Fig. 1c and d) when com-
pared with benign prostate hyperplasia samples (BPH;
Fig. 1a and b). Intriguingly, human ADAM19 expression
is reduced as the severity of prostate cancer rises (Fig. 1c
and d) which is a novel finding.
High ADAM19 expression correlates with increased
disease-free survival from prostate cancer, and lower
tumour stage
In order to evaluate the relationship between ADAM19
levels and prostate cancer, we studied ADAM19 expres-
sion in publicly available microarray data from two
distinct cohorts of prostate cancer patients. In the
GSE40272 cohort (Fig. 2a), there was a significant
association between high median ADAM19 expression
levels and reduced cancer relapse (Hazard Ratio 0.1749,
p < 0.003). The clinicopathological characteristics of the
GSE40272 cohort is presented in Table 1.
In the TCGA cohort (Fig. 2b) we found that high
ADAM19 expression in prostate cancer tissue was
significantly negatively associated with tumour stage
(cor = -0.18, p < 0.026). There were few deaths in the
TCGA cohort, preventing any meaningful association
of ADAM19 expression to overall survival. However,
the TCGA cohort showed that high ADAM19 expres-
sion was highly associated with lower tumour stage,
which taken together with the strong association of
high ADAM19 expression with higher disease free
survival, provides substantial evidence that ADAM19
is a marker of improved prognosis in prostate cancer.
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LNCaP cells proliferate at a faster rate than RWPE-1 cells
Having demonstrated that high levels of ADAM19
mRNA expression correlate with increased disease free
survival and lower tumour stage in publicly available
prostate cancer microarray databases, we then sought to
determine the ADAM19 expression levels in human
tumorigenic LNCaP prostate cancer cells and normal
RWPE-1 prostate epithelial cells.
To ensure that our cells were displaying expected
proliferative capacity, we conducted proliferation as-
says with LNCaP and RWPE-1 cells. As expected, we
found that LNCaP cells proliferated significantly faster
*
A B
C D
Fig. 1 Immunostaining of ADAM19 and its correlation with severity in human prostate cancer. ADAM19 immunostaining of (a) normal prostate,
exhibiting hyperplasia; (b) prostate hyperplasia; (c) malignant prostate adenocarcinoma, grade II; and (d) malignant prostate adenocarcinoma, grade III.
Photomicrographs are 200X magnification. Asterisk indicates stroma and arrow indicates glandular hyperplasia. ADAM19 staining is brown in colour.
Haematoxylin counterstaining is purple in colour
Fig. 2 High ADAM19 expression correlates with increased disease-free survival and is associated with lower tumour stage. a Kaplan-Meier survival
curve of the GSE40272 human prostate cancer cohort (n = 71). Relapse follow up is 80 months; p < 0.002. b TCGA prostate cancer boxplot of ADAM19
expression and tumour stage; p < 0.03; cor -0.179; n = 156
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(p < 0.05) than normal RWPE-1 prostate epithelial
cells at 1, 3 and 5 days post-seeding (Additional file
1: Figure S1).
LNCaP cells express lower levels of ADAM19 compared to
RWPE-1 cells
We next investigated the level of expression of ADAM19
protein in LNCaP cells and normal RWPE-1 cells. As
shown in Fig. 3a, human ADAM19 is endogenously
expressed in both LNCaP and RWPE-1 cells, but to dif-
ferent degrees. The 80 and 45 kD bands were observed
at considerably higher levels in RWPE-1 cells, consistent
with the notion that ADAM19 may act as a tumor sup-
pressor in prostate cancer cells. Furthermore, RWPE-1
cells showed higher expression of endogenous ADAM19
protein in immunocytochemistry experiments (Fig. 3b).
In addition, we found the intracellular expression of
ADAM19 was cytoplasmic and heterogenous in both
LNCaP and RWPE-1 cells. Taken together, these data
suggest that normal prostate cells express significantly
higher levels of ADAM19 compared to their tumorigenic
counterparts.
Verification that human ADAM19 is bioactive and cleaves
human TNF-α
To determine the bioactivity of ADAM19 in our over-
expression system, we conducted transfections in HEK293
cells. We showed that ADAM19 is readily over-expressed
in HEK293 cells and that it is predominantly cytoplasmic
and heterogeneous in distribution (Additional file 1:
Figure S2A). Transfection efficiency, as determined
using a GFP vector, was greater than 70 % (Additional
file 1: Figure S3). Next we validated that we could use
shedding of the pro-inflammatory cytokine TNF-α, a
known substrate for ADAM19 [26, 27], as a bioassay
for ADAM19 activity. Co-transfection of vectors ex-
pressing human TNF-α and human ADAM19 in
HEK293 cells resulted in significantly increased TNF-α
shedding (17-fold; p < 0.0001) (Additional file 1: Figure
Table 1 Clinical information on the GSE40272 prostate cancer cohort
Patient feature High ADAM19 (n) Low ADAM19 (n) Total (n)
All cases 77 (100 %)
ADAM19 evaluated 36 (50.7 %) 35 (49.3 %) 71 (92.2 %)
Age at diagnosis
≤54 7 (43.8 %) 9 (56.3 %) 16 (22.5 %)
55-64 14 (45.2 %) 17 (54.8 %) 31 (43.7 %)
≥ 65 15 (62.5 %) 9 (37.5 %) 24 (33.8 %)
Cancer stage
II 4 (80 %) 1 (20 %) 5 (7 %)
III 23 (46.9 %) 26 (53.1 %) 49 (69 %)
IV 7 (47.7 %) 8 (53.3 %) 15 (21.1 %)
Unknown 2 (100 %) 0 (0 %) 2 (2.8 %)
Gleason score
6 7 (47.7 %) 8 (53.3 %) 15 (21.1 %)
7 26 (55.3 %) 21 (44.7 %) 47 (66.2 %)
8 1 (33.3 %) 2 (66.7 %) 3 (4.2 %)
9 1 (20 %) 4 (80 %) 5 (7 %)
Unknown 1 (100 %) 0 (0 %) 1 (1.4 %)
PSA levels (ng/mL)
< 5 15 (45.5 %) 18 (54.5 %) 33 (46.5 %)
5-6.9 12 (80 %) 3 (20 %) 15 (21.1 %)
≥ 7 7 (35 %) 13 (65 %) 20 (28.2 %)
Unknown 2 (66.7 %) 1 (33.3 %) 3 (4.2 %)
Tumour recurrence
Yes 5 (29.4 %) 12 (70.6 %) 17 (23.9 %)
No 29 (56.9 %) 22 (43.1 %) 51 (71.8 %)
Unknown 2 (66.7 %) 1 (33.3 %) 3 (4.2 %)
Clinicopathological features relative to ADAM19 mRNA expression levels in prostate tumours
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S2B). This confirmed in our system that ADAM19 can
induce TNF-α cleavage, and generated a simple and re-
liable tool of its function. As PC3 prostate cancer cells
are known to express TNF-α at the mRNA level, we
also aimed to assess whether over-expression of ADAM19
in these cells may promote shedding of endogenous TNF-
α. Unfortunately, no TNF-α protein was detected in cell-
free culture supernatants after ADAM19 over-expression
in PC3 cells (data not shown).
Over-expression of human ADAM19 in LNCaP cells
reduces proliferation
We then aimed to ascertain the direct effects of
ADAM19 over-expression on human prostate cancer
cell proliferation. LNCaP cells were an ideal cell line for
these studies, given their lower endogenous levels of
ADAM19 (Fig. 3a and b). As shown in Fig. 4a, we were
able to effectively overexpress ADAM19 in LNCaP cells,
evidenced by strong cytoplasmic diaminobenzidine
staining. Transfection efficiency, as assessed with a green
fluorescent protein (GFP) expression vector, was more
than 50 % (Additional file 1: Figure S4).
The effect of ADAM19 over-expression on LNCaP cell
proliferation was determined by MTS assays performed
3, 5 and 7 days after transfection. Figure 4b shows that
the proliferation rate of LNCaP cells overexpressing
ADAM19 is significantly slower than LNCaP cells ex-
pressing empty vector (p < 0.05). Photomicrographs of
LNCaP cells taken 7 days post-transfection (Fig. 4c)
reinforce the LNCaP MTS proliferation assay results.
Taken together, these data suggest that over-expression
of human ADAM19 in LNCaP cells reduces proliferation.
Over-expression of human ADAM19 in PC3 cells reduces
migration and increases cell death
Lastly, we examined the impact of ADAM19 over-
expression on human prostate cancer cell migration.
Androgen-independent PC3 cells were utilised because
of their low endogenous expression of ADAM19 (Fig. 5a)
LNCaP RWPE-1
100 kDa
75 kDa
50 kDa
37 kDa
LN
C
aP
R
W
P
E
-1
ADAM19
ADAM19
-actin
A
B
Fig. 3 Human prostate cancer cells express lower levels of ADAM19 than normal prostate epithelial cells. a Western blotting for ADAM19 protein
in androgen-sensitive human LNCaP cells and RWPE-1 cells. β-actin was used as a control. b ADAM19 protein expression in LNCaP and RWPE-1
cells as determined by immunocytochemistry. 100x magnification. Insert shows cytoplasmic staining
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and ability to consistently grow in a monolayer. The ef-
fect of ADAM19 over-expression on PC3 cell migration
was evaluated with an in vitro scratch assay conducted
on transfected PC3 cells. We show for the first time that
ADAM19 over-expression hinders migration of PC3
cells reproducibly compared with cells transfected with
empty vector, 24 h post-transfection (Fig. 5b). This mi-
gration pattern was also observed 48 h after the initial
transfection (data not shown). In addition, we assessed
the cellular viability of PC3 cells 48 h after transfection.
We found that ADAM19 transfected PC3 cells experi-
enced statistically significant higher cell death than
empty vector transfected cells (Fig. 5c) which is a novel
discovery.
Discussion
We have shown for the first time that ADAM19 may
serve as a tumor suppressor in human prostate cancer.
Our examination of microarray data from two independ-
ent human prostate cancer cohorts indicated that high
ADAM19 expression was associated with almost a six-
fold increase in disease free survival and a significantly
lower tumour stage. These data prompted us to further
investigate the direct effect of ADAM19 in human pros-
tate cancer cells. We found that ADAM19 expression is
reduced in human prostate cancer cells compared to
normal prostate epithelial cells.
Interestingly and in contrast to our findings herein,
previous studies have demonstrated that higher ADAM19
expression may be pro-oncogenic and is considered to
play a role in driving development of human ovarian and
renal cancer [28, 29] and increased expression is associ-
ated with human brain tumour invasiveness [30]. Thus, al-
though ADAM19 appears to be involved in driving other
cancers, it appears to have the opposite effect in human
prostate cancer. Over-expression of human ADAM19 in
LNCaP or PC3 cells reduced the proliferation rate and mi-
gration of these cells respectively. Collectively, these find-
ings suggest that ADAM19 is a beneficial factor in
prostate cancer and functions by decreasing proliferation
and migration.
Although our study suggests that ADAM19 is a
tumour suppressor in prostate cancer, the mechanism is
still to be elucidated. There are numerous potential can-
didate proteins which are known to be either substrates
or binding proteins of ADAM19. Examples of substrates
include Neuregulin 1-β1 [31], TNF-α [26, 27, 32], and
cysteine-rich protein 2 (CRIP-2) [33]. The binding pro-
teins include α4β1 and α5β1 integrins [20]. ADAM19’s
metalloproteinase domain is involved in the catalytically-
mediated ectodomain shedding of substrates [15]. One
Fig. 4 Human LNCaP cells are able to have ADAM19 over-expressed and ADAM19 over-expression reduces LNCaP cell proliferation. a LNCaP
cells were transfected with either empty vector (pCR3.1) or human ADAM19 vector (pCR3.1 hADAM19) for 48 h before conducting ADAM19
immunocytochemistry. 100x magnification. Insert shows cytoplasmic staining of over-expressed ADAM19. b LNCaP cell proliferation was measured by
MTS assay 3, 5, and 7 days after cells were transfected with empty vector or ADAM19 expressing vector. Mean + SEM. c Photomicrographs of LNCaP
cells transfected with empty vector (pCR3.1) or ADAM19 expressing vector (pCR3.1 hADAM19) after 7 days post-transfection. 100x magnification;
n = 12 samples/cell type/time point; *p < 0.05
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substrate cleaved by ADAM19 is Neuregulin 1-β1 [31].
This substrate has been identified to bind to the tyrosine
kinase receptors ErbB3 and ErbB4 to result in tyrosine
residue phosphorylation. This ultimately affects cardiac
development and morphogenesis [34–36]. Grasso et al.
(1997) [37] demonstrated that Neuregulin binding to
ErbB3 and ErbB4 ligands inhibited LNCaP growth. In
mice, the shedding of Neuregulin 1-β1 appeared to be
enhanced by ADAM19’s transmembrane domain [38].
The cleavage of Neuregulin 1-β1 by ADAM19 may there-
fore signify a possible anti-tumourigenic mechanism in
human prostate cancer.
The pro-inflammatory cytokine TNF-α is another sub-
strate that ADAM19 has been shown to cleave in a var-
iety of settings [26, 27, 32]. Chopra et al. (2004) [39]
determined that LNCaP cells are sensitive to TNF-α
stimulated growth arrest and apoptosis. TNF-α has been
shown to induce apoptosis in human prostate cancer cell
lines mainly through the NFκB pathway, however, it ap-
pears that this may be partly dependent upon androgen
sensitivity [39, 40]. Our data indicates that ADAM19 in-
duces TNF-α shedding in HEK293 cells, and further
studies are required to elucidate the effect of TNF-α
shedding by ADAM19 and it’s role in human prostate
cancer. We are aware from our current study, that
ADAM19 appears not to be shedding endogenous TNF-
α from PC3 prostate cancer cells.
The cysteine-rich domain enables ADAM19 to pos-
sess autolytic processing activity. ADAM19’s cysteine-
rich and disintegrin domains associate with CRIP2 to
result in the release of CRIP-2 [33]. This tumour-
suppressor protein reduces tumourigenesis and angio-
genesis in nasopharyngeal cancer cell lines and tu-
mours [41]. CRIP-2 also promotes apoptosis of
esophageal cancer cells [42]. Importantly, CRIP-2 is
known to be expressed by LNCaP cells [43] as well as
normal prostate epithelial cells [44], however the ex-
pression differences between normal and cancerous
prostate tissue in humans remains to be explored. AD-
AM19’s ability to increase secretion of CRIP-2 may repre-
sent another possible anti-tumourigenic mechanism for
ADAM19 in prostate cancer [33].
It has been shown that ADAM19 inhibits migration
mediated by the α4β1 and α5β1 integrins by binding to
these integrins with its disintegrin domain [20]. Hence,
ADAM19 neutralises the actions of α4β1 and α5β1
integrins. The integrin α4β1 normally binds to fibronec-
tin, causing growth factor and tumour-induced lym-
phangiogenesis [21]. Integrin α5β1 usually mediates
fibronectin adhesion necessary for prostate cancer me-
tastasis [45]. Excitingly, neutralisation of the activity of
α4β1 and α5β1 by ADAM19 may be a mechanism by
which this metalloproteinase reduces the progression of
prostate cancer. Interestingly, we have also shown that
over-expression of ADAM19 in PC3 human prostate
carcinoma cells inhibits migration of these cells. Future
studies will address whether this is mediated by inter-
action of ADAM19 with integrins.
It is interesting to speculate regarding the post-
translational modifications that may be at play in pros-
tate cancer and may contribute to the reduced ADAM19
expression in prostate cancer. Further studies should
aim to assess whether the ADAM19 gene is hypermethy-
lated and silenced in prostate cancer [46].
An exciting avenue for future investigation is the study of
single nucleotide polymorphisms (SNPs) within ADAM19
in human prostate cancer. London et al. [47] identified that
a nonsynonymous serine to glycine substitution within
ADAM19 (rs1422795) could affect human pulmonary func-
tion. The functional relevance of rs1422795 on ADAM19
expression is currently unknown. It will be of interest to as-
sess if there are any polymorphisms that reduce human
ADAM19 expression, particularly in the prostate cancer
environment.
Conclusions
Our study provides evidence that elevated ADAM19 ex-
pression may serve as a tumor suppressor in human pros-
tate cancer. Using human normal and prostate cancer
biopsies, we show that ADAM19 protein levels are ele-
vated in normal prostate and reduced in prostate cancer
specimens. Our clinical data from two different cohorts
provides compelling results for involvement of ADAM19
in prostate cancer and our in vitro data shows that
ADAM19 can regulate prostate cancer cell growth and
migration. Intriguingly, it would appear that the effects of
ADAM19 may be limited to prostate cancer cells with re-
duced expression of ADAM19. These data provide for the
first time a foundation to further explore the mechanism
(See figure on previous page.)
Fig. 5 ADAM19 over-expression hinders human PC3 prostate cancer cell migration and increases death in PC3 cells. a PC3 cells were transfected
with either empty vector (pCR3.1) or human ADAM19 vector (pCR3.1 hADAM19) for 48 h before conducting ADAM19 immunocytochemistry
(100x magnification). Insert shows cytoplasmic staining of over-expressed ADAM19 (200x magnification). b Photomicrographs depict PC3 cell
migration 0 and 24 h post-transfection with either empty vector or human ADAM19 vector (40x magnification). Images are representative of 4
individual wells. c A trypan blue count was conducted on empty vector or human ADAM19 vector transfected cells after 48 h of transfection;
*p < 0.005; n = 4
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by which ADAM19 exerts its tumor suppressor effects
and raises the possibility that expression of ADAM19
levels in prostate cancer tumors could become a useful
biomarker in the disease.
Additional file
Additional file 1: Figure S1. Human prostate cancer cells proliferate
faster than normal prostate epithelial cells. Cell proliferation was measured
by MTS assay 1, 3 and 5 days after cells were seeded (0.25x105 cells/mL on
day 0); n = 12 samples/cell type/time point; mean +/- SEM; *p < 0.05. Figure
S2. Over-expression of human TNF-α with human ADAM19 in HEK293 cells
promotes TNF-α shedding. (A) HEK293 cells were transfected with either
empty vector (pCR3.1) or human ADAM19 vector (pCR3.1 hADAM19). Insert
shows cytoplasmic staining of over-expressed ADAM19. 100x magnification.
(B) Comparison of HEK293 cells transfected with ADAM19 expression vector
alone, TNF-α vector alone or co-transfected with both vectors; mean +/-
SEM; *p = 0.0004; **p < 0.0001. Figure S3. Transfection efficiency in HEK293
cells 48 h post-transfection. Phase contrast (A) and green fluorescent protein
(GFP) positivity (B). 100x magnification. Figure S4. Transfection efficiency in
LNCaP cells 48 h post-transfection. Phase contrast (A) and green fluorescent
protein (GFP) positivity (B). 100x magnification. (DOCX 1817 kb)
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